Neurodegenerative Diseases
An Introduction to Neurodegenerative Diseases
Huntington’s Disease (HD) is a rare, incurable, inherited and ultimately fatal neurodegenerative disorder characterised by chorea, ataxia, dysphagia, cognitive and behavioural changes. Current therapies offer only symptomatic relief, and many are associated with significant side effects, though pridopidine, a sigma-1-receptor (S1R) agonist has shown potential for both symptomatic treatment and disease modifying effects in HD. Advances in our understanding of the pathogenesis of HD have highlighted the importance of DNA repair genes, and novel approaches, such as the antisense therapy tominersen and the oral agent branaplam, are targeting the mutant huntingtin (mHTT) protein and the HTT gene. However, no disease-modifying therapy is yet approved for HD.
Our supporting partners do not constitute an endorsement of the content on this page.
Prof. Arcadi Navarro discusses BBRC's largest-ever presence at AAIC, the growing role of biomarkers and personalized risk prediction, and why prevention is becoming the future of Alzheimer's disease research. Introduction We spoke with Prof. Arcadi Navarro, Professor of Genetics and ...
Dr Reisa Sperling discusses the rationale for targeting preclinical Alzheimer's disease, the latest long-term data from the Brainshuttle AD programme evaluating trontinemab, and how the PrevenTRON study could help shift Alzheimer's disease treatment towards prevention. We spoke with Dr Reisa ...
Prof. George Grossberg discusses the unmet need in agitation associated with Alzheimer's disease, the rationale behind the phase 3 ADAGIO studies, and the evolving role of biomarkers and caregivers in improving patient care. We spoke with Prof. George Grossberg, Saint Louis ...
Could biomarker-driven Alzheimer’s care widen existing disparities? Lessons from the New IDEAS study
Large real-world study highlights important ethnoracial differences in amyloid positivity and their implications for diagnosis, treatment and clinical trial access As amyloid biomarkers become central to Alzheimer's disease diagnosis and treatment, a new analysis from the New IDEAS (Imaging Dementia—...
Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...
We are delighted to announce Dr Björn Vahsen as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in amyotrophic lateral sclerosis and related neurodegenerative diseases Dr Björn Vahsen (Nuffield ...
We are delighted to announce Dr Brandon Holmes as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Brandon Holmes (Memory and Aging Center and Weill Institute ...
We are delighted to announce Dr Rebecca Casterton as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Rebecca Casterton (University of Cape Town, Cape Town, South ...
We are delighted to announce Dr Erdi Sahin as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Erdi Sahin, an Assistant Professor in the Department of ...
Prof. Lutz Frölich discusses the 48-month Clarity AD open-label extension, including long-term efficacy, clinical meaningfulness, safety and what these findings could mean for patients eligible for lecanemab in Europe. At the European Academy of Neurology (EAN) Congress 2026, Prof. Lutz ...
Recent omaveloxolone updates include progress in the phase 3 BRAVE study, development of a liquid-ready formulation and evolving reimbursement discussions across multiple regions Phase 3 BRAVE study advances pediatric development in Friedreich’s ataxia Biogen is continuing to expand the clinical development ...
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
Findings from AAN 2026 highlight a potential “survival paradox” associated with GLP-1 analogue use in older adults with diabetes At American Academy of Neurology 2026, Isaac Thorman (New York Medical College, Valhalla, NY, USA) presented new real-world data exploring the relationship between ...
New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
